We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years; assisting our clients to develop and bring new drugs to market while improving the lives of their patients across the world.
The Dishman Group was founded in 1983 by Janmejay R. Vyas, Chairman of the Dishman Group. Since its inception, the Dishman Group's focus has been on research and development of various in-house technologies for the manufacture of quaternary ammonium compounds (quats) and active pharmaceutical ingredients.
The Dishman Group's first facility was built in 1987 in Naroda; in 1996 the company initiated its expansion at Bavla, its current headquarters. Through several acquisitions, the Dishman Group spread its reach across the globe with multiple manufacturing facilities in India, Europe and China-serving pharmaceutical and biopharmaceutical companies.
“I saw the need for a company that could provide high-quality, high-value products and services and be a good, reliable partner to pharmaceutical companies worldwide. Having a competitive cost-base and efficient operations is important, but what’s really key is the quality of our people, the service they provide, and the value they offer to our pharmaceutical customers.”
Janmejay R. Vyas
Since then, with the acquisition of Carbogen Amcis AG in 2006 and its vitamin and cholesterol business in 2007, Dishman Carbogen Amcis Ltd has become a global force in innovative product and service and development. Staying true to our founding principles, the business continues to advance with energetic leadership and an unparalleled focus on innovation; with the driving ambition of improving the lives of humankind.
Our objective is to help our customers create a better world, as the partner of choice for the development and manufacture of complex and challenging substances, highly-potent active ingredients and breaking new ground with innovative vitamin, healthcare and industrial products.
Dishman Carbogen Amcis focusses on the reduction of operational risk in chemical development and commercial manufacturing by:
•• Minimising the time associated with drug development
•• Decreasing the risks associated with drug development
•• Providing long-term and value-added contract manufacturing solutions
© 2021 Dishman Carbogen Amcis Ltd - All Rights Reserved